220 related articles for article (PubMed ID: 36441501)
1. Futibatinib: First Approval.
Syed YY
Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
[TBL] [Abstract][Full Text] [Related]
2. Futibatinib for
Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
[TBL] [Abstract][Full Text] [Related]
3. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
De SK
Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
[TBL] [Abstract][Full Text] [Related]
4. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract][Full Text] [Related]
5. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma.
Hoy SM
Target Oncol; 2024 May; 19(3):473-480. PubMed ID: 38724820
[TBL] [Abstract][Full Text] [Related]
6. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract][Full Text] [Related]
8. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
9. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
Rengan AK; Denlinger CS
J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
[TBL] [Abstract][Full Text] [Related]
10. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
Noé C; Edeline J
Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
[No Abstract] [Full Text] [Related]
11. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
[TBL] [Abstract][Full Text] [Related]
12. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N
Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673
[TBL] [Abstract][Full Text] [Related]
13. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
14. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
15. Futibatinib (Lytgobi) for cholangiocarcinoma.
Med Lett Drugs Ther; 2023 Apr; 65(1674):e69-e70. PubMed ID: 37039618
[No Abstract] [Full Text] [Related]
16. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
18. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
Lamarca A; Vogel A
ESMO Open; 2023 Dec; 8(6):102049. PubMed ID: 37922686
[No Abstract] [Full Text] [Related]
19. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Uson Junior PLS; Borad MJ
Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]